From teprotide to captopril: Rational design of ACE inhibitors;Vom teprotid zum captopril: Rationales design von ACE-Hemmern

Pharmazie in Unserer Zeit

Volumn 32, Issue 1, 2003, Pages 11-16

  Nemec, Karin ^a   Schubert Zsilavecz, Manfred ^a  

^a Institut fur Pharmazeutische Chemie   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BENAZEPRIL; BENAZEPRILAT; CAPTOPRIL; CARBOXYPEPTIDASE A; CILAZAPRIL; CILAZAPRILAT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ENALAPRILAT; FOSINOPRIL; FOSINOPRILAT; LISINOPRIL; MOEXIPRIL; MOEXIPRILAT; PERINDOPRIL; PERINDOPRILAT; PRODRUG; QUINAPRIL; QUINAPRILAT; RAMIPRIL; RAMIPRILAT; SPIRAPRIL; SPIRAPRILAT; TEPROTIDE; TRANDOLAPRIL; TRANDOLAPRILAT;

ARTICLE; BLOOD PRESSURE REGULATION; DRUG DESIGN; DRUG STRUCTURE; HUMAN; HYPERTENSION; NEUTROPENIA; NONHUMAN; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SIDE EFFECT; SNAKE;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CAPTOPRIL; DRUG DESIGN; HUMANS; PEPTIDYL-DIPEPTIDASE A; TEPROTIDE;

EID: 0037253054     PISSN: 00483664     EISSN: None     Source Type: Journal    
DOI: 10.1002/pauz.200390001     Document Type: Article

References (16)

1. Tigerstedt R, Bergman PG. Skand Arch Physiol 1898; 8: 233-271.
2. Goldblatt H, Lynch J, Hanzal RF, Summerville WW. Studies on experimental hypertension. J Exp Med 1934; 59: 347-379.
3. Page IH, Helmer OM. A crystalline pressor substance (angiotonin) resulting from the reaction between renin and renin activator. J Exp Med 1940; 71: 29-42.
4. Braun-Menendez E, Fasciolo C, Leloir LF, Munoz M. The substance causing renal hypertension. J Physiol 1940; 98: 282-298.
5. Skeggs LT, Kahn JR, Shumway NP. The preparation and function of the hypertensin-converting enzyme. J Exp Med 1956; 103: 295-299.
6. Elliott OF, Peart WS. Amino acid sequence in a hypertensin. Nature 1956; 177: 527-528.
7. Bumpus FM, Schwarz H, Page IH. Synthesis and pharmacology of the octapeptide angiotonin. Science 1957; 125: 886-887.
8. 5-Hypertensins I. Helvet Chim Acta 1958; 41: 1273-1286.
9. Cushman DW, Ondetti MA. History of the design of captopril and related inhibitors of angiotensin converting enzyme. Hypertension 1991; 17(4): 589-592.
10. Ferreira SH. A bradykinin-potentiating factor (BPF) present in the venom of Bothrops jararaca. Br J Pharmacol 1965; 24: 163-169.
11. Byers LD, Wolfenden R. Binding of the biproduct analog benzylsuccinic acid by carboxypeptidase A. Biochemistry 1973; 12: 2070-2078.
12. Cushman DW, Ondetti MA, Gordon EM et al. Rational design and biochemical utility of specific inhibitors of angiotensin-converting enzyme. J Cardiovasc Pharmacol 1987; 10: S17-S30.
13. Ondetti MA, Cushman DW. Angiotensin-converting enzyme inhibitors: biochemical properties and biological actions. CRC Crit Rev Biochem 1984; 16: 381-411.
14. Rocha e Silva M, Beraldo WT, Rosenfeld G. Bradykinin hypotensive and smooth muscle stimulating factor released from plasma globulin by snake venoms and by trypsin. Am J Physiol 1949; 156: 261-273.
15. Ferreira SH. A bradykinin-potentiating factor (BPF) present in the venom of Bothrops jararaca. Br J Pharmacol 1965; 24: 163-169.
16. Yang HYT, Erdoes EG, Levin Y. A dipeptidyl carboxypeptidase that converts angiotensin I and inactivates bradykinin. Biochem Biophys Acta 1970; 214: 374-376.